Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
KEYVIBE-010 adjuvant vibostolimab + pembrolizumab versus pembrolizumab in high-risk resected melanoma
MOH_2022-12-12_012229Phase 3Active, not recruiting
- Sponsor
- Merck & Co.
- Start
- Dec 2022
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of vibostolimab and pembrolizumab in melanoma (2 arms), sponsored by Merck & Co. Primary endpoints: Safety and Efficacy. Started Dec 2022; status: active, not recruiting.
02
Drugs
vibostolimabpembrolizumab
03
Conditions
melanoma
Beyond the preview
Go deeper on MOH_2022-12-12_012229.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2022-12-12_012229.